Federated Hermes’s Alder Biopharmaceuticals ALDR Stock Holding History

Federated Hermes’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-35	Closed	-$1K	–	2378
2018 Q3	$1K	Buy	+35	New	+$633	﹤0.01%	2238

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Federated Hermes's ALDR Position: Q4 2018 in Review

Federated Hermes sold out of Alder Biopharmaceuticals (ALDR) in Q4 2018, closing a stake of 35 shares — an estimated $1K sold.

Federated Hermes first reported a position in ALDR in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 124 funds tracked by Wall St. Rank hold ALDR as of Q4 2018.

Federated Hermes reported no remaining Alder Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
Federated Hermes sold 35 Alder Biopharmaceuticals shares in Q4 2018, an estimated $1K.
Federated Hermes first reported a position in Alder Biopharmaceuticals in Q3 2018 and held it in 1 quarter.
Federated Hermes's Alder Biopharmaceuticals position peaked at $1K in Q3 2018.
124 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2018.

Based on Federated Hermes's 13F filing for Q4 2018, filed 13 Feb 2019.